OncoSil Medical (ASX:OSL) ROCE % : -218.16% (As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is OncoSil Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OncoSil Medical's annualized ROCE % for the quarter that ended in Dec. 2024 was -218.16%.

OncoSil Medical ROCE % Historical Data

The historical data trend for OncoSil Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSil Medical ROCE % Chart

OncoSil Medical Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

-26.16

-61.51

-98.95

-106.98

-170.28

OncoSil Medical Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial															-132.08	-144.80	-190.67	-258.30	-218.16

OncoSil Medical ROCE % Calculation

OncoSil Medical's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	-12.375	/	( ( (11.474 - 1.569)	+	(6.359 - 1.729) )	/ 2 )
	=	-12.375	/	( (9.905	+	4.63)	/ 2 )
	=	-12.375	/	7.2675
	=	-170.28 %

OncoSil Medical's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	-14.428	/	( ( (6.359 - 1.729)	+	(11.5 - 2.903) )	/ 2 )
	=	-14.428	/	( ( 4.63	+	8.597 )	/ 2 )
	=	-14.428	/	6.6135
	=	-218.16 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

OncoSil Medical (ASX:OSL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OncoSil Medical ROCE % Related Terms

Thank you for viewing the detailed overview of OncoSil Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSil Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OncoSil Medical Ltd (ASX:OSL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113

Website

https://www.oncosil.com

OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.

OncoSil Medical Headlines

No Headlines